Tcr2 Therapeutics Stock Shares Outstanding

TCRRDelisted Stock  USD 1.48  0.00  0.00%   
Tcr2 Therapeutics fundamentals help investors to digest information that contributes to Tcr2 Therapeutics' financial success or failures. It also enables traders to predict the movement of Tcr2 Stock. The fundamental analysis module provides a way to measure Tcr2 Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tcr2 Therapeutics stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Tcr2 Therapeutics Company Shares Outstanding Analysis

Tcr2 Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Shares Outstanding

 = 

Public Shares

-

Repurchased

More About Shares Outstanding | All Equity Analysis

Current Tcr2 Therapeutics Shares Outstanding

    
  39.26 M  
Most of Tcr2 Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tcr2 Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition

Based on the latest financial disclosure, Tcr2 Therapeutics has 39.26 M of shares currently outstending. This is 78.25% lower than that of the Biotechnology sector and 63.26% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 93.13% higher than that of the company.

Tcr2 Shares Outstanding Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tcr2 Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tcr2 Therapeutics could also be used in its relative valuation, which is a method of valuing Tcr2 Therapeutics by comparing valuation metrics of similar companies.
Tcr2 Therapeutics is currently under evaluation in shares outstanding category among its peers.

Tcr2 Fundamentals

About Tcr2 Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Tcr2 Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tcr2 Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tcr2 Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with Tcr2 Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tcr2 Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tcr2 Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Tcr2 Stock

  0.65SSNLF Samsung ElectronicsPairCorr

Moving against Tcr2 Stock

  0.77MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.73KO Coca Cola Sell-off TrendPairCorr
  0.64TLK Telkom Indonesia TbkPairCorr
  0.6PPERF Bank Mandiri PerseroPairCorr
  0.55PPERY Bank Mandiri PerseroPairCorr
The ability to find closely correlated positions to Tcr2 Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tcr2 Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tcr2 Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tcr2 Therapeutics to buy it.
The correlation of Tcr2 Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tcr2 Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tcr2 Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tcr2 Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Other Consideration for investing in Tcr2 Stock

If you are still planning to invest in Tcr2 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tcr2 Therapeutics' history and understand the potential risks before investing.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Money Managers
Screen money managers from public funds and ETFs managed around the world
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years